Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT06038227

Lung cAncer Robotic Comparative Study

Lung cAncer Robotic Comparative Study — Recruiting • Oncology • NCT06038227.

📅 06 Apr 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06038227
Sponsor
Intuitive Surgical
Start
2023-07-15
ClinicaliQ Trial Snapshot
  • Lung cAncer Robotic Comparative Study — Recruiting • Oncology • NCT06038227.
  • To compare outcomes of minimally invasive surgical techniques for the treatment of early-stage non-small cell lung cancer.
  • Sponsor: Intuitive Surgical.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

To compare outcomes of minimally invasive surgical techniques for the treatment of early-stage non-small cell lung cancer.

Eligibility Snapshot
  • : * Patient diagnosed with clinical stage IA1-2 non-small cell lung cancer at time of procedure * Patient scheduled to undergo minimally invasive surgery for NSCLC with either da Vinci robotic assisted surgery or VATs * Aged ≥ 18 years * Must be willing and able to comply with study requirements * Must indicate their understanding of the study and willingness to participate by signing an appropriate informed consent form

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
Oncology · 16 Jun 2026
First-line treatment option: Cemiplimab combined with platinum-based chemotherapy is recommended by NICE for patients with untreated advanced non-small-cell lung cancer (NSCLC), offering…
View guideline →
Guideline
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Oncology · 18 Jun 2026
Serplulimab combined with carboplatin and etoposide is recommended as first-line treatment for untreated extensive-stage small-cell lung cancer (ES-SCLC) and should be considered…
View guideline →
Guideline
Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)
Oncology · 04 Jun 2026
Nogapendekin alfa inbakicept combined with BCG is no longer recommended for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ in the UK,…
View guideline →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Guideline
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy
Oncology · 09 Jul 2026
Cemiplimab is recommended as a treatment option for patients with recurrent or metastatic cervical cancer only after progression on or following platinum-based…
View guideline →